ONWARD Medical Raises €40.6M for Spinal Cord Injury Therapies

ONWARD Medical, a Dutch neurotechnology firm dedicated to restoring mobility and independence for individuals with spinal cord injuries, has successfully closed a significant capital raise, securing €40.6 million in gross proceeds. This funding injection, achieved through an accelerated bookbuild private placement, will accelerate the development and commercialization of its innovative spinal cord stimulation therapies.

The substantial investment saw participation from a cohort of institutional investors, with a notable €25 million commitment originating from EQT Life Sciences. This financial backing is a strong endorsement of ONWARD Medical's progress and its potential to revolutionize treatment for movement disorders. The company's CEO, Dave Marver, expressed enthusiasm for the transaction, highlighting its role in advancing the company's mission and validating the market's reception of its ARC-EX® System.

ONWARD Medical's proprietary ARC Therapy utilizes targeted spinal cord stimulation to reanimate paralyzed limbs. The company's flagship ARC-EX® System, an external device, has already garnered FDA Breakthrough Device Designations and secured commercial approval in both the United States and Europe. This system represents a critical step in offering functional recovery to patients with spinal cord injuries, a field with significant unmet medical needs and a growing market driven by an aging population and increased incidence of traumatic injuries.

Further bolstering its therapeutic pipeline, ONWARD Medical is advancing its investigational implantable system, ARC-IM®. This next-generation technology aims to address complex challenges such as autonomic dysreflexia, a life-threatening condition characterized by blood pressure instability post-spinal cord injury. The ARC-IM® platform is designed for integration with advanced technologies like brain-computer interfaces (BCI) and artificial intelligence, paving the way for thought-controlled movement and enhanced autonomic regulation.

The newly acquired capital will be strategically allocated to fuel ONWARD Medical's ambitious growth plans. Approximately 40% will be directed towards research and development initiatives, focusing on the clinical studies and regulatory pathways for the ARC-IM® System. Another 30% is earmarked for expanding sales and operational infrastructure to support the commercial rollout of the ARC-EX® System across key global markets. The remaining funds will bolster quality assurance, administrative functions, and general corporate needs, extending the company's cash runway into the first quarter of 2028.

The neurotechnology sector, particularly in areas addressing neurological disorders, is experiencing robust investor interest. Companies developing innovative solutions for conditions like spinal cord injury are attracting significant capital as the potential for transformative patient outcomes and substantial market penetration becomes increasingly evident. ONWARD Medical's successful funding round positions it favorably within this dynamic and promising market.